Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00987844 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation

A Phase 3 study of Chronic Constipation, sponsored by Movetis.

Completed
Registry status
Phase 3
Development phase
1,775
Enrollment target
1
Study location

NCT00987844 is a Phase 3 study of Chronic Constipation that has completed, run by Movetis. The registered enrollment target is 1,775 participants, above the 349-participant average among 4 other Chronic Constipation trials with a reported enrollment target (409% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00987844, a Phase 3 study of Chronic Constipation, has completed, sponsored by Movetis.

COMPLETED
Registry status
Phase 3
Development phase
1,775 participants
Enrollment target
1
Study location

Study Summary

Objectives: To evaluate the clinical long-term safety and the tolerability, patient satisfaction, pharmacokinetics and use of pattern of prucalopride given in doses up to 4 mg per day to patients with chronic constipation (CC).

Conditions Studied

Interventions

  • DRUG Prucalopride

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 1,775 participants
Start Date 1998-07
Phase Phase 3

Sponsor

Movetis

1 total trials

What the Registry Record Tells You About NCT00987844

The ClinicalTrials.gov registry entry for NCT00987844 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,775 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 349-participant average among 4 other Chronic Constipation trials with a reported enrollment target (409% higher). The listed sponsor is Movetis, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Constipation appearing as the primary indexed condition, and to 1 intervention - of which Prucalopride is the first listed.

NCT00987844 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00987844 about?

NCT00987844 is a clinical study titled "Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation". Objectives: To evaluate the clinical long-term safety and the tolerability, patient satisfaction, pharmacokinetics and use of pattern of prucalopride given in doses up to 4 mg per day to patients with chronic constipation (CC).

What is the current status of trial NCT00987844?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,775 participants. The study started on 1998-07.

What conditions does trial NCT00987844 study?

This clinical trial studies the following conditions: Chronic Constipation.

What interventions are being tested in trial NCT00987844?

The interventions under investigation include: Prucalopride (DRUG).

Who is sponsoring clinical trial NCT00987844?

This trial is sponsored by Movetis, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00987844 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Constipation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.